QuintilesIMS Wins Society for Clinical Research Sites’ 2016 Eagle Award
October 18 2016 - 7:30AM
Business Wire
Commitment to enhancing site relationships
recognized for fourth consecutive year
QuintilesIMS (NYSE:Q) announced today that it has been awarded
the 2016 Eagle Award from the Society for Clinical Research Sites
(SCRS) for the fourth consecutive year. Presented during the annual
SCRS Site Solutions Summit, the site-nominated award recognizes
contract research organizations (CRO) and biopharmaceutical
sponsors dedicated to building positive relationships with research
sites through leadership, professionalism and integrity.
“We are honored to bring this award home again by focusing on
what really matters to sites,” said Cynthia Verst, president,
Clinical Operations at QuintilesIMS. “This award once again
recognizes our focus on enhancing our site relationships and
delivering best-in-class site facing operations. I would like to
thank our talented teams, as well as the sites and clients with
whom we partner, for their support as we work together to help our
customers drive healthcare forward.”
"QuintilesIMS' commitment to site relationships has been
demonstrated in their repeated placement as a finalist or winner of
the CRO Eagle Award," said Christine Pierre, president of SCRS.
"The bar continues to rise as CROs develop processes that support
site sustainability and we applaud all of the Eagle Award
finalists."
In advance of the Site Solutions Summit, SCRS members and
clinical research site professionals globally were invited to vote
for the CRO and sponsor they felt demonstrated a strong commitment
to site partnerships. Criteria also considered for this award
included patient safety, timely enrollment and effective
communication to optimize study success.
For more information about the SCRS Eagle Award, visit
http://sitesolutionssummit.com/eagle-awards/.
About QuintilesIMS
QuintilesIMS (NYSE:Q) is a leading integrated information and
technology-enabled healthcare service provider worldwide, dedicated
to helping its clients improve their clinical, scientific and
commercial results. Formed through the merger of Quintiles and IMS
Health, QuintilesIMS’s approximately 50,000 employees conduct
operations in more than 100 countries. Companies seeking to improve
real-world patient outcomes and enhanced clinical trial outsourcing
through treatment innovations, care provision and access can
leverage QuintilesIMS’s broad range of healthcare information,
technology and service solutions to drive new insights and
approaches. QuintilesIMS provides solutions that span clinical to
commercial bringing clients a unique opportunity to realize the
full potential of innovations and advance healthcare outcomes.
As a global leader in protecting individual patient privacy,
QuintilesIMS uses healthcare data to deliver critical, real-world
disease and treatment insights. Through a wide variety of
privacy-enhancing technologies and safeguards, QuintilesIMS
protects individual privacy while managing information to drive
healthcare forward. These insights and execution capabilities help
biotech, medical device, and pharmaceutical companies, medical
researchers, government agencies, payers and other healthcare
stakeholders in the development and approval of new therapies,
identify unmet treatment needs and understand the safety,
effectiveness and value of pharmaceutical products in improving
overall health outcomes. To learn more, visit
www.QuintilesIMS.com.
Click here to subscribe to Mobile Alerts for QuintilesIMS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018005611/en/
Quintiles Media RelationsPhil Bridges, +1-919-998-1653
(office)+1-919-457-6347
(mobile)phil.bridges@quintiles.comorQuintilesIMS Media RelationsTor
Constantino,
+1-484-567-6732tor.constantino@quintilesims.comorQuintilesIMS,
Investor RelationsTom Kinsley,
+1-203-448-4691tom.kinsley@quintilesims.comorQuintiles Investor
RelationsTodd Kasper,
+1-919-998-2590todd.kasper@quintilesims.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2024 to May 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From May 2023 to May 2024